MedTrace Logo

A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)

NCT06681623 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2024-11-18

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety of ublituximab use in the older MS adult population, as measured by incidence of infection rate

Conditions

  • Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis

Interventions

DRUG

Ublituximab

Drug: ublituximab

Sponsors & Collaborators

  • Neurology Center of New England P.C.

    lead OTHER

Eligibility

Min Age
55 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-13
Primary Completion
2027-09-30
Completion
2027-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06681623 on ClinicalTrials.gov